Welcome to our dedicated page for Akili news (Ticker: AKLI), a resource for investors and traders seeking the latest updates and insights on Akili stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Akili's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Akili's position in the market.
Akili, Inc. (Nasdaq: AKLI) announced its participation in the Biotech Showcase and Solebury 1x1 Management Access Conference, scheduled for January 11 in San Francisco. CEO Eddie Martucci will participate as a panelist in the Biotech Showcase Future Panel: Digital Therapeutics in The Next Decade. The company will also meet with investors during the J.P. Morgan Healthcare Conference.
Akili has published promising topline results from the STARS-ADHD-Adolescents study, showcasing the efficacy of EndeavorRx in treating ADHD in adolescents aged 13-17. The study achieved a significant improvement in attention functioning after four weeks, exceeding results from previous trials. The company plans to file for a label expansion with the FDA in 2023. Recruitment for a concurrent adult trial has been paused for earlier data analysis, with 224 patients currently enrolled.
Akili, Inc. has appointed Dr. Scott Kollins as Chief Medical Officer, effective December 1, 2022. Dr. Kollins, a leading expert in ADHD, will enhance Akili's mission to innovate treatment options, starting with its digital therapeutic product, EndeavorRx. The appointment aims to bolster the company's growth and clinical evidence generation in ADHD treatment, an area that has seen little change in over 50 years. EndeavorRx is the first FDA-authorized treatment for ADHD delivered through a video game experience, targeting cognitive impairments in children aged 8 to 12.
Akili, Inc. (Nasdaq: AKLI) reported Q3 2022 financial results, highlighting significant growth in its video game treatment, EndeavorRx. The number of prescribers surged by 91% to 789, with prescriptions climbing to over 1,300—up 71% quarter-over-quarter. The company raised $164 million from its business combination, positioning itself for future expansion. Cash reserves reached $156.4 million, expected to sustain operations until mid-2024. Despite a net income of $53.2 million, total operating expenses rose to $24.5 million due to stock-based compensation and other costs.
Akili, Inc. announced the appointment of Mary Hentges to its board of directors, effective October 25, 2022. Hentges, former CFO at PayPal and CBS Interactive, will chair the Audit Committee and serve on the Compensation Committee. Her extensive experience in high-growth companies is expected to support Akili's growth strategy, particularly with the commercialization of its flagship product, EndeavorRx. Co-founder Eddie Martucci emphasized Hentges' leadership as crucial for establishing prescription digital therapeutics in clinical care.
Akili, Inc. (NASDAQ: AKLI) will host a conference call on November 10, 2022, at 4:30 p.m. ET to discuss its third-quarter financial results. The call will be accessible via a live audio webcast on the company’s website, with an archived version available afterward. Akili is recognized for its pioneering work in cognitive treatments utilizing engaging video game technologies, aimed at addressing cognitive impairments through clinically validated methods. For more details, visit www.akiliinteractive.com.
Akili Interactive announced the launch of the EndeavorRx Expedition product registry, aimed at collecting real-world data from patients prescribed EndeavorRx. This fully remote registry allows caregivers and patients to provide insights into usage patterns and effectiveness, which will guide product improvements. EndeavorRx, the first FDA-cleared prescription video game for ADHD in children ages 8-12, has been evaluated in five clinical trials with over 600 participants. The registry is crucial for enhancing the evidence base for physicians and payors.
Akili, Inc. (Nasdaq: AKLI) has announced its participation in the LifeSci Partners HealthTech Symposium on September 20, 2022. The company will engage in a fireside chat at 9:30 a.m. ET and a panel discussion on prescription digital therapeutics at 11:30 a.m. ET. Both presentations will be accessible via live and archived webcasts on Akili's website. Akili is known for developing cognitive treatments using gaming technologies that target cognitive impairments, validated through clinical trials.
Akili, Inc. announced its common stock will trade on Nasdaq under the ticker symbol AKLI starting on August 22, 2022. The company successfully completed a business combination with Social Capital Suvretta Holdings Corp. I (ticker DNAA) and raised more than $163 million for its operations. The funds will support the commercial launch of EndeavorRx, the first FDA-cleared video game treatment for pediatric ADHD, and advance its pipeline targeting neuropsychiatric diseases. CEO Eddie Martucci emphasized the company's commitment to innovative digital medicine.